Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
451
archived clinical trials in
Rheumatology

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1319
mi
from
San Jose, CA
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1319
mi
from
San Jose, CA
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marlton, NJ
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
750
mi
from
Athens, TN
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
750
mi
from
Athens, TN
Click here to add this to my saved trials
Multi-Colored Placido Disk Viability
Viability Study of a Multi-Colored Videokeratoscope With Extended Timescale Data
Status: Enrolling
Updated:  12/31/1969
The Flaum Eye Institute-University of Rochester
1121
mi
from
Rochester, NY
Multi-Colored Placido Disk Viability
Viability Study of a Multi-Colored Videokeratoscope With Extended Timescale Data
Status: Enrolling
Updated: 12/31/1969
The Flaum Eye Institute-University of Rochester
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
1444
mi
from
Boston, MA
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1306
mi
from
Mineola, NY
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1306
mi
from
Mineola, NY
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1053
mi
from
Duncansville, PA
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1053
mi
from
Duncansville, PA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Berlin,
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Berlin,
Click here to add this to my saved trials
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
262
mi
from
Omaha, NE
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
262
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)
Status: Enrolling
Updated:  12/31/1969
Penn State Hershey Medical Center Department of Dermatology
1147
mi
from
Hershey, PA
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)
Status: Enrolling
Updated: 12/31/1969
Penn State Hershey Medical Center Department of Dermatology
1147
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)
Status: Enrolling
Updated:  12/31/1969
Pediatric and General Dermatology
1112
mi
from
Fairfax, VA
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)
Status: Enrolling
Updated: 12/31/1969
Pediatric and General Dermatology
1112
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1339
mi
from
San Francisco, CA
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1123
mi
from
Bethesda, MD
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
971
mi
from
Pittsburgh, PA
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
971
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Brest Cedex,
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects With Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Brest Cedex,
Click here to add this to my saved trials
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Implementation of Rapid Infusion Rituximab in a Pilot Group of Adolescents With Hematologic, Oncologic, and Rheumatologic Disorders
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
572
mi
from
Houston, TX
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
Implementation of Rapid Infusion Rituximab in a Pilot Group of Adolescents With Hematologic, Oncologic, and Rheumatologic Disorders
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
572
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Bayview Medical Center
1151
mi
from
Baltimore, MD
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Bayview Medical Center
1151
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
NorthEast Rheumatology
968
mi
from
Concord, NC
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
NorthEast Rheumatology
968
mi
from
Concord, NC
Click here to add this to my saved trials
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
1053
mi
from
Duncansville, PA
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
1053
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
5763
mi
from
Sofia,
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
5763
mi
from
Sofia,
Click here to add this to my saved trials
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
New Mexico Clinical Research & Osteoporosis Center
522
mi
from
Albuquerque, NM
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
New Mexico Clinical Research & Osteoporosis Center
522
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated:  12/31/1969
San Francisco VA Medical Center, San Francisco, CA
1339
mi
from
San Francisco, CA
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated: 12/31/1969
San Francisco VA Medical Center, San Francisco, CA
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
1148
mi
from
Baltimore, MD
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated:  12/31/1969
Durham VA Medical Center, Durham, NC
1047
mi
from
Durham, NC
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated: 12/31/1969
Durham VA Medical Center, Durham, NC
1047
mi
from
Durham, NC
Click here to add this to my saved trials
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated:  12/31/1969
VA Caribbean Healthcare System, San Juan, PR
2332
mi
from
San Juan,
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated: 12/31/1969
VA Caribbean Healthcare System, San Juan, PR
2332
mi
from
San Juan,
Click here to add this to my saved trials
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Regional VA Medical Center, Aurora, CO
401
mi
from
Aurora, CO
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Secondary Event Prevention Using Population Risk Management After PCI
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Regional VA Medical Center, Aurora, CO
401
mi
from
Aurora, CO
Click here to add this to my saved trials
Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome
Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome
Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Tufts University School of Dental Medicine
1444
mi
from
Boston, MA
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Tufts University School of Dental Medicine
1444
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Wallace Rheumatic Study Center
1175
mi
from
Beverly Hills, CA
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Wallace Rheumatic Study Center
1175
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Denver Arthritis Clinic
404
mi
from
Denver, CO
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Denver Arthritis Clinic
404
mi
from
Denver, CO
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinic Foundation
638
mi
from
Baton Rouge, LA
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinic Foundation
638
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
John Hopkins Bayview Medical Center
1148
mi
from
Baltimore, MD
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
John Hopkins Bayview Medical Center
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
University of Michigan
808
mi
from
Ann Arbor, MI
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
University of Michigan
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
1306
mi
from
Mineola, NY
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
1306
mi
from
Mineola, NY
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Shanahan Rheumatology & Immunology, PLLC
1057
mi
from
Raleigh, NC
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Shanahan Rheumatology & Immunology, PLLC
1057
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
MetroHealth System
893
mi
from
Cleveland, OH
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
MetroHealth System
893
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
1053
mi
from
Duncansville, PA
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
1053
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Reading, LLC
1183
mi
from
Wyomissing, PA
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Reading, LLC
1183
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Ramesh Gupta
467
mi
from
Memphis, TN
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Ramesh Gupta
467
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Hopital Avicenne, Paris
4721
mi
from
Bobigny,
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Hopital Avicenne, Paris
4721
mi
from
Bobigny,
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Local Institution
563
mi
from
Tupelo, MS
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Local Institution
563
mi
from
Tupelo, MS
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Local Institution
1305
mi
from
Mineola, NY
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Local Institution
1305
mi
from
Mineola, NY
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Local Institution
970
mi
from
Wexford, PA
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Local Institution
970
mi
from
Wexford, PA
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Pharmacology Study Group
1405
mi
from
Worcester, MA
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Pharmacology Study Group
1405
mi
from
Worcester, MA
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
PMG Research of Wilmington
1135
mi
from
Wilmington, NC
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
PMG Research of Wilmington
1135
mi
from
Wilmington, NC
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Paramount Medical Research & Consulting, Llc
887
mi
from
Middleburg Heights, OH
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Paramount Medical Research & Consulting, Llc
887
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
1053
mi
from
Duncansville, PA
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
1053
mi
from
Duncansville, PA
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Tekton Research
517
mi
from
Austin, TX
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Tekton Research
517
mi
from
Austin, TX
Click here to add this to my saved trials
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated:  12/31/1969
Local Institution
8650
mi
from
Camperdown,
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome
Status: Enrolling
Updated: 12/31/1969
Local Institution
8650
mi
from
Camperdown,
Click here to add this to my saved trials